Glide raises $4m for phase I trial of solid-dose teriparatide

Glide Technologies said today that it raised £3.2 million, or $4.0 million USD, in a round of financing. A number of existing investors contributed to the round, according to the Oxford-based company.
Glide plans to use the funds to finish phase I trials this year for its solid dose formulation of a parathyroid hormone, teriparatide.
Get the full story at our sister site, Drug Delivery Business News.
The post Glide raises $4m for phase I trial of solid-dose teriparatide appeared first on MassDevice.

Source: Mass Device - February 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Funding Roundup Pharmaceuticals Wall Street Beat Glide Technologies Source Type: news